08048035996
Afanat 30 mg Tablet UK Wholesale – Manchester | Competitive Prices | Phoenix Exim | Trusted Exporter

1. General Information

Afanat 30 mg Tablet is an oral anticancer medicine containing afatinib 30 mg. It is used under specialist medical supervision for certain patients with non-small cell lung cancer (NSCLC), particularly tumors with specific epidermal growth factor receptor (EGFR) alterations. Afatinib is a targeted cancer therapy rather than a conventional chemotherapy medicine.

For Phoenix Exim, Afanat 30 mg can be presented as a pharmaceutical export product from Nagpur, India, subject to the prescription, import, and pharmaceutical regulations applicable in the destination country.

2. Product Information

  • Brand: Afanat 30 mg Tablet
  • Active ingredient: Afatinib
  • Strength: 30 mg
  • Dosage form: Oral film-coated tablet
  • Drug class: Tyrosine kinase inhibitor (TKI)
  • Therapeutic category: Anticancer / targeted therapy
  • Primary indication: Certain forms of non-small cell lung cancer
  • Manufacturer/Marketer: Natco Pharma Ltd. for the Afanat 30 mg product listed in India
  • Prescription status: Prescription medicine
  • Storage: Store according to the product packaging/label instructions.

3. Uses of Afanat 30 mg

Afanat 30 mg is used for certain patients with non-small cell lung cancer (NSCLC).

Afatinib is particularly used in patients whose tumors have specific EGFR mutations. Official prescribing information for afatinib includes first-line treatment of metastatic NSCLC with non-resistant EGFR mutations and treatment of metastatic squamous NSCLC progressing after platinum-based chemotherapy.

The appropriate indication depends on the patient's cancer type, molecular testing results, previous treatment and overall medical condition.

4. Benefits of Afanat 30 mg

The potential benefits of afatinib include:

  • Provides targeted treatment for selected EGFR-mutated NSCLC.
  • Helps inhibit abnormal signaling that can promote cancer-cell growth.
  • May slow progression of certain EGFR-driven lung cancers.
  • Offers an oral treatment option rather than an injectable therapy.
  • Can be used as part of a specialist-directed treatment plan for eligible patients.

The benefit of treatment depends on the patient's specific cancer characteristics and EGFR status. It should not be considered appropriate for every lung-cancer patient.

5. Side Effects of Afanat 30 mg

Like other targeted anticancer medicines, afatinib can cause side effects. Important possible reactions include:

  • Diarrhea
  • Skin rash or acne-like dermatitis
  • Dry skin
  • Mouth inflammation or sores
  • Nausea
  • Vomiting
  • Reduced appetite
  • Itching
  • Nail inflammation/infection around the nails
  • Eye irritation or dryness

Some adverse reactions can become serious and may require treatment interruption or dose adjustment by the treating oncologist.

6. Common Side Effects

The commonly reported adverse effects of afatinib include:

Diarrhea: This is one of the most frequent side effects and can sometimes become severe.

Skin reactions: Rash, acne-like skin reactions, dryness and itching may occur.

Mouth problems: Stomatitis, mouth ulcers or irritation can develop.

Nausea and vomiting: Some patients may experience gastrointestinal symptoms.

Nail problems: Inflammation around the fingernails or toenails can occur.

Loss of appetite: Reduced appetite may occur during treatment.

Patients should tell their healthcare provider if side effects become persistent, severe or difficult to manage.

7. How to Use Afanat 30 mg

Afanat 30 mg should be taken only according to the oncologist's prescription.

General administration guidance includes:

  • Take the tablet at approximately the same time each day.
  • It is generally taken on an empty stomach.
  • Swallow the tablet whole with water.
  • Do not crush or chew it unless specifically instructed by a healthcare professional.
  • Do not change the prescribed dose yourself.
  • If a dose is missed, follow the instructions provided by the treating doctor or product information.

The dose can vary according to the patient's condition, tolerability and other clinical factors. The 30 mg strength may be prescribed as a dose adjustment in appropriate patients; therefore, patients should not select the strength themselves.

8. How Afanat 30 mg Works

Afatinib is a tyrosine kinase inhibitor. It blocks signaling through members of the ErbB receptor family, including EGFR.

In certain lung cancers, abnormal EGFR signaling can contribute to uncontrolled cancer-cell growth. By inhibiting these signaling pathways, afatinib can interfere with signals that help cancer cells grow and survive.

This targeted mechanism is why testing for relevant molecular alterations is important before treatment in appropriate patients.

9. Safety Advice

  • Use Afanat 30 mg only under the supervision of a qualified oncologist.
  • EGFR mutation testing may be required to determine whether afatinib is appropriate.
  • Report severe or persistent diarrhea promptly because dehydration can occur.
  • Inform your doctor about liver or kidney problems before treatment.
  • Tell your healthcare team about all prescription medicines, OTC medicines and supplements you take because interactions can occur.
  • Protect your skin from excessive sunlight and use appropriate sun protection if advised.
  • Report significant skin reactions, severe mouth sores or eye symptoms.
  • Seek urgent medical attention for new or worsening breathing difficulties.
  • Afatinib can cause fetal harm; pregnancy and breastfeeding require specific medical advice.
  • Keep the medicine away from children and store it according to the package instructions.

Important: This information is for general product education and pharmaceutical catalog content. Afanat 30 mg is a prescription anticancer medicine and should not be promoted as suitable for self-medication.

10. Frequently Asked Questions

Q1. What is Afanat 30 mg Tablet?

Afanat 30 mg is an oral tablet containing afatinib, a targeted anticancer medicine used for certain types of non-small cell lung cancer.

Q2. What is the active ingredient in Afanat 30 mg?

The active ingredient is afatinib 30 mg, supplied as afatinib dimaleate.

Q3. What is Afanat 30 mg used for?

It is used for selected cases of non-small cell lung cancer, particularly cancers with specific EGFR alterations.

Q4. Is Afanat 30 mg a chemotherapy medicine?

Afatinib is generally classified as a targeted therapy/tyrosine kinase inhibitor, rather than traditional cytotoxic chemotherapy.

Q5. Can Afanat 30 mg be taken without a prescription?

No. It should be used only under the supervision of an appropriate healthcare professional.

Q6. Should Afanat 30 mg be taken with food?

Afatinib is generally taken on an empty stomach. Follow the specific instructions provided by the prescribing doctor and product information.

Q7. What are the most common side effects?

Diarrhea, rash, dry skin, mouth inflammation, nausea, decreased appetite and nail inflammation are among commonly reported reactions.

Q8. Can the Afanat dose be changed?

Dose adjustments may be required depending on tolerability and medical circumstances. Any dose change must be made by the treating healthcare professional.

11. Substitutes for Afanat 30 mg

Possible alternatives containing afatinib 30 mg may include other brands/generics of afatinib, depending on the country and market availability.

Examples may include:

  • Afatin 30 mg Tablet
  • Other approved afatinib 30 mg tablets
  • Gilotrif 30 mg (afatinib)

However, a substitute should not be selected solely by brand name. The treating oncologist or pharmacist should confirm the active ingredient, strength, formulation, regulatory status and suitability for the patient. Afatinib products may not be interchangeable with other EGFR inhibitors without medical direction.

12. SEO & B2B Keywords

Product Keywords

  • Afanat 30 mg Tablet
  • Afanat 30 mg
  • Afatinib 30 mg Tablet
  • Afatinib 30 mg supplier
  • Afatinib 30 mg exporter
  • Afatinib tablets manufacturer India
  • Afatinib medicine exporter India
  • Afatinib 30 mg pharmaceutical supplier
  • Afatinib 30 mg wholesale supplier
  • Afatinib anticancer medicine supplier
  • Afatinib lung cancer medicine
  • Afatinib EGFR inhibitor
  • Afatinib targeted therapy
  • Afatinib tablets for NSCLC

Export & B2B Keywords

  • Afanat 30 mg exporter from India
  • Afatinib 30 mg exporter from Nagpur
  • Afatinib medicine supplier from India
  • Afanat 30 mg wholesale exporter
  • Afatinib pharmaceutical exporter India
  • Afatinib 30 mg international supplier
  • Afatinib 30 mg B2B pharmaceutical supplier
  • Afatinib 30 mg export supplier
  • Afatinib 30 mg supplier USA
  • Afatinib 30 mg supplier UK
  • Afatinib 30 mg supplier Australia
  • Afatinib 30 mg supplier Singapore
  • Afatinib 30 mg supplier Canada
  • Afatinib 30 mg supplier South Korea
  • Afatinib 30 mg supplier UAE
  • Afanat 30 mg pharmaceutical export from India
  • Afatinib oncology medicine exporter
  • Afatinib generic medicine supplier India
  • Afatinib 30 mg bulk pharmaceutical supplier
  • Afatinib 30 mg international pharma exporter
Aug 12th, 2026 3:33 PM

Keywords